#None #Class Action #stock decline #Capricor Therapeutics

Capricor Therapeutics Faces Class Action Amidst Stock Crash

In a shocking turn of events, investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) have found themselves facing unexpected challenges following a steep decline in stock value. The firm Levi & Korsinsky, LLP is now notifying these shareholders of a securities class action filed on their behalf. The lawsuit covers those who bought CAPR securities between December 17, 2025, and July 26, 2026, and aims to address the significant losses incurred due to misleading information.

A Journey from Hope to Disillusionment

On August 22, 2026, expectations were high as the FDA was due to announce its decision on Capricor's application. Investors were optimistic, buoyed by promising statistical results and the company’s proactive statements about its commercial plans. However, this optimism turned to disillusionment when alarming FDA briefing documents were disclosed, which reportedly pointed to unapproved changes in the statistical analysis plan that were detrimental to the study's validity.

By the close of trading on July 30, 2026, Capricor's stock price plummeted to $4.19 per share, a staggering fall of approximately 78.7% from its Class Period high of $35.34 back on April 21, 2026. This decline was not just a market fluctuation but rather a reaction to severe revelations regarding the FDA's stance on Capricor's product efficacy.

The Breakdown of Trust

The pivotal moment for investors occurred on July 27, 2026, when the FDA released briefing documents stating that the clinical study failed to meet its primary and secondary endpoints. According to the reports, the final statistical analysis plan was created the day before the study's unblinding, raising serious doubts about the integrity of the data used to support the product's launch.

This led to an advisory committee voting 9-3 against the efficacy of Capricor’s treatment for DMD-associated cardiomyopathy. Not only did this outcome shake investor confidence, but it also reflected poorly on Capricor's transparency, with claims emerging that shareholders were kept in the dark about critical information.

Investor Actions and Class Action Details

As a response to these events, Levi & Korsinsky has mobilized to support affected investors, urging them to contact the firm for a free evaluation of their case. The deadline to act as a lead plaintiff is September 28, 2026. With the impending class action, shareholders are encouraged to gather all relevant brokerage documents, including purchase dates, share quantities, and pricing.

Important Questions Addressed

How severe was the stock drop? The stock saw a total decline of $15.08 per share following two critical disclosures, marking an aggregate drop of 78.7%.

When did the alleged misrepresentation occur? The Class Period spans from December 17, 2025, to July 26, 2026, during which critical information that could have impacted stock values was kept from investors.

What’s the next step for investors? Those affected are urged to compile necessary documentation and contact Levi & Korsinsky to evaluate their eligibility for compensation, regardless of whether they still own shares in the company.

As the class action progresses, it underscores the vital importance of transparency within securities markets and the responsibilities companies hold toward their investors. Any investor who feels wronged during this turbulent period is encouraged to seek legal advice and consider joining the class action to recover their losses.

For further details or to inquire, investors can contact Levi & Korsinsky directly via phone at (212) 363-7500 or through their website.